Gilead Sciences
MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst
February 10, 2016Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C
The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …
Gilead Sciences names John Milligan new CEO
January 29, 2016Medical Communications, Sales and Marketing Gilead Sciences, John Martin, John Milligan
Gilead Sciences has announced that chairman and chief executive John Martin is to step down after 20 years at the …
Gilead steps in to rescue Galapagos RA drug
December 18, 2015Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis
Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …
Gilead’s Sovaldi wins Drug Discovery of the Year Award
December 16, 2015Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi
Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …
EU approval for Gilead’s HIV combo Genvoya
December 1, 2015Manufacturing and Production, Sales and Marketing European Commission, Genvoya, Gilead, Gilead Sciences, HIV, TDF, World Aids Day, european union, taf
Gilead Sciences has won marketing authorisation from the European Commission (EC) for the once-daily single tablet regimen Genvoya as an …
FDA expands Gilead’s Harvoni indications for Hep C
November 13, 2015Sales and Marketing Gilead, Gilead Sciences, harvoni, ledipasvir-sofosbuvir
Gilead’s Harvoni has been approved by the FDA for expanded use in patients with genotypes 4, 5 and 6 chronic …
Gilead presents Phase III results for Genvoya in HIV
October 22, 2015Medical Communications, Research and Development Genvoya, Gilead Sciences, HIV
Gilead Sciences has today announced 96-week results from two Phase III studies evaluating its investigational once-daily single tablet regimen (STR), …
NICE approves first in new class of leukaemia drugs
September 24, 2015Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig
NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …
Latest content
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner
